We used proteomics to characterize the insoluble subproteome of C. difficile strain 630. Gel-based LC-MS analysis led to the identification of 2298 peptides;

provalt analysis with a false discovery rate set at 1% concatenated this list to 560 unique peptides, resulting Selleck Dasatinib in 107 proteins being positively identified. These were functionally classified and physiochemically characterized and pathway reconstruction identified a variety of central anaerobic metabolic pathways, including glycolysis, mixed acid fermentation and short-chain fatty acid metabolism. Additionally, the metabolism of a variety of amino acids was apparent, including the reductive branch of the leucine fermentation pathway, from which we identified seven of the eight enzymes. Increasing proteomics data sets should – in conjunction with other ‘omic’ technologies – allow the construction of models for ‘normal’ metabolism in C. difficile 630. This would be a significant initial step towards a full systems understanding of this clinically important microorganism. The Gram-positive spore-forming anaerobe Clostridium difficile, first described by Hall & O’Toole (1935), has become recognized as the leading cause of infectious

diarrhoeal in hospital patients worldwide over the last three decades (Riley, 1998; Sebaihia et al., 2007). Two factors are significant in the increased prevalence of C. difficile infection (CDI): the increase in the use of broad-spectrum antibiotics, including find more cephalosporins Phospholipase D1 and aminopenicillins (Poutanen & Simor, 2004), and the widely reported contamination of the hospital environment by C. difficile spores (Durai, 2007). Antibiotic-associated diarrhoeal and colitis were well established soon after antibiotics became available, with C. difficile being identified as the major cause of antibiotic-associated diarrhoeal and as the nearly exclusive cause of potentially life-threatening pseudomembranous colitis in 1978 (Bartlett, 2006). Clostridium difficile’s well-documented antibiotic resistance results in its persistence when the normal gut microbial communities are disturbed or eradicated by antibiotic

therapy, following which C. difficile spores germinate, producing vegetative cells, which, upon proliferation, secrete the organism’s two major virulence factors – toxin A and toxin B. As the major virulence factors, the toxins have been studied extensively in order to dissect C. difficile virulence mechanisms and they are the primary markers for the diagnosis of CDI (reviewed extensively elsewhere – e.g. Voth & Ballard, 2005; Jank et al., 2007; Lyras et al., 2009). The toxins lead to the development of symptoms associated with CDI, ranging from mild, self-limiting watery diarrhoeal, to mucosal inflammation, high fever and pseudomembranous colitis (Bartlett & Gerding, 2008). Recently, a new epidemic of C. difficile, associated with the emergence of a single hypervirulent strain of C.